Showing 4711-4720 of 10520 results for "".
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global
- UCB’s Bimekizumab Outplays the Competition in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ucbs-bimekizumab-outplays-the-competition-in-two-phase-3-psoriasis-trials/2460764/UCB’s Bimekizumab almost entirely cleared moderate to severe psoriasis in more than 60 percent of the patients who took part in two Phase 3 clinical trials. Given via injection under the skin, Bimekizumab is a monoclonal antibody and the first to block both Interleukin 17A and Int
- Fat Grafting Shows Promise for Cancer Patients with Radiation-induced Skin Injuryhttps://practicaldermatology.com/news/fat-grafting-shows-promise-for-cancer-patients-with-radiation-induced-skin-injury/2460730/As cancer survival rates improve, more people are living with the aftereffects of cancer treatment including chronic radiation-induced skin injury. Fat grafting procedures may unleash the healing and regenerative power of the body's natural adipose stem cells (ASCs). "Prelimina
- Kenneth J. Tomecki, MD, FAAD is New President of the AADhttps://practicaldermatology.com/news/kenneth-j-tomecki-md-faad-is-new-president-of-the-aad/2460723/Kenneth J. Tomecki, MD, FAAD is now president of the American Academy of Dermatology (AAD). During his one-year term, Dr. Tomecki will lead the world’s largest dermatologic society, representing more than 20,000 physicians specializing
- Study: Clear Masks Improve Communication with Patientshttps://practicaldermatology.com/news/study-clear-masks-improve-communication-with-patients/2460716/Seeing really is believing. New research shows that doctors who wear transparent face masks greatly improve communication with patients compared to doctors whose faces are blocked by a standard face masks. What’s more, providers who wore the ClearMask are also perc
- New from Solta: Meet the Next Generation Clear + Brilliant Laserhttps://practicaldermatology.com/news/new-from-solta-meet-the-next-generation-clear-brilliant-laser/2460711/Solta Medical is launching Clear + Brilliant Touch laser, the company’s next generation Clear + Brilliant laser. By seamlessly switching between two wavelengths with the Original and Perméa handpieces, physicians can now more easily deliver a
- Baricitinib Performs Well in Phase 3 AA Trialhttps://practicaldermatology.com/news/baricitinib-performs-well-in-phase-3-aa-trial/2460709/Eli Lilly and Company and Incyte’s Baricitinib is the first JAK inhibitor to demonstrate hair regrowth in a Phase 3 alopecia areata (AA) trial. Patients with severe alopecia areata who took baricitinib 2-mg or 4-mg once daily showed a statistically significant improvemen
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident
- Breaking Business News: Evolus' Jeuveau Can Stay on U.S. Market For Nowhttps://practicaldermatology.com/news/breaking-business-news-evolus-jeuveau-can-stay-on-us-market-for-now/2460690/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to
- NRS Survey Finds Rosacea Patients Lack Knowledge of Antibiotic Resistancehttps://practicaldermatology.com/news/nrs-survey-finds-rosacea-patients-lack-knowledge-of-antibiotic-resistance/2460671/A majority of rosacea patients have never heard of antibiotic resistance, results of a recent survey by the National Rosacea Society (NRS) show. Yet topical or oral antibiotics are among the most commonly prescribed treatments for rosacea. The NRS’s rec